Table 4 Analysis of clinical features in de novo stress urinary incontinence (SUI) group (n = 24) and no SUI group (n = 53).

From: Predictors for de novo stress urinary incontinence following pelvic reconstruction surgery with transvaginal single-incisional mesh

 

De novo SUI group (n = 24)

No SUI group (n = 53)

p value†

OR (95% CI)‡

Age (years)

<64

6 (25.0)

28 (52.8)

 

1 (reference)

≥64

18 (75.0)

25 (47.2)

0.023

3.36 (1.15–9.79)

Parity

<4

16 (66.7)

35 (66.0)

 

1 (reference)

≥4

8 (33.3)

18 (34.0)

0.96

0.97 (0.35–2.70)

BMI (kg/m2)

Healthy <24

10 (41.7)

31 (58.5)

  

Overweight 24–30

14 (58.3)

20 (37.7)

  

Obese >30

0

2 (3.8)

0.13

—

Past history

HRT

1 (4.2)

2 (3.8)

1.0

0.90 (0.08–10.46)

Menopause

23 (95.8)

49 (92.5)

1.0

0.53 (0.06–5.04)

H/T

10 (41.7)

22 (41.5)

0.99

0.99 (0.37–2.64)

DM

4 (16.7)

7 (13.2)

0.73

0.76 (0.20–2.89)

Hysterectomy

5 (20.8)

9 (17.0)

0.75

0.77 (0.23–2.63)

Previous POP or SUI surgery

2 (8.3)

5 (9.4)

1.0

1.15 (0.21–6.37)

Prolapse

Stage II

2 (8.3)

8 (15.1)

 

1 (reference)

Stage III – IV

22 (91.7)

45 (84.9)

0.72

1.96 (0.38–9.99)

Anterior wall prolapse

23 (95.8)

45 (84.9)

0.17

0.24 (0.03–2.08)

Apical prolapse

18 (75.0)

41 (77.4)

0.82

1.14 (0.37–3.51)

Isolated uterine prolapse

0

6 (11.3)

0.17

—

Posterior wall prolapse

5 (20.8)

9 (17.0)

0.75

0.78 (0.23–2.63)

POP-Q

Aa ≥ 2

14 (58.3)

19 (35.9)

0.065

0.40 (0.15–1.07)

Ba ≥ 4

12 (50.0)

15 (28.3)

0.065

0.39 (0.15–1.07)

C ≥ 3

7 (29.2)

15 (28.3)

0.94

0.96 (0.33–2.78)

TvL ≥ 10

11 (45.8)

15 (28.3)

0.13

0.47 (0.17–1.27)

  1. †Fisher’s exact test and χ2 test were performed for categorical variables.
  2. ‡The univariate logistic regression was applied for odds ratios and 95% confidence intervals.
  3. *OR: odds ratios; CI: confidence intervals; BMI: body mass index; HRT: hormone replacement therapy; H/T: hypertension; DM: diabetes mellitus; POP: pelvic organ prolapse; SUI: stress urinary incontinence.
Back to article page